JP7769603B2 - デオキシシチジンの多形形態、それを含む組成物および使用 - Google Patents

デオキシシチジンの多形形態、それを含む組成物および使用

Info

Publication number
JP7769603B2
JP7769603B2 JP2022510955A JP2022510955A JP7769603B2 JP 7769603 B2 JP7769603 B2 JP 7769603B2 JP 2022510955 A JP2022510955 A JP 2022510955A JP 2022510955 A JP2022510955 A JP 2022510955A JP 7769603 B2 JP7769603 B2 JP 7769603B2
Authority
JP
Japan
Prior art keywords
ppm
deoxycytidine
less
mixture
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022510955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544831A (ja
Inventor
グリッデン,ポール
Original Assignee
ユーシービー バイオサイエンシズ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオサイエンシズ,インコーポレイテッド filed Critical ユーシービー バイオサイエンシズ,インコーポレイテッド
Publication of JP2022544831A publication Critical patent/JP2022544831A/ja
Priority to JP2025116467A priority Critical patent/JP2025160233A/ja
Application granted granted Critical
Publication of JP7769603B2 publication Critical patent/JP7769603B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2022510955A 2019-08-19 2020-08-19 デオキシシチジンの多形形態、それを含む組成物および使用 Active JP7769603B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116467A JP2025160233A (ja) 2019-08-19 2025-07-10 デオキシシチジンの多形形態、それを含む組成物および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888893P 2019-08-19 2019-08-19
US62/888,893 2019-08-19
PCT/US2020/047047 WO2021034962A1 (en) 2019-08-19 2020-08-19 Polymorphic forms of deoxycytidine, compositions comprising the same and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116467A Division JP2025160233A (ja) 2019-08-19 2025-07-10 デオキシシチジンの多形形態、それを含む組成物および使用

Publications (2)

Publication Number Publication Date
JP2022544831A JP2022544831A (ja) 2022-10-21
JP7769603B2 true JP7769603B2 (ja) 2025-11-13

Family

ID=74647126

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022510955A Active JP7769603B2 (ja) 2019-08-19 2020-08-19 デオキシシチジンの多形形態、それを含む組成物および使用
JP2025116467A Pending JP2025160233A (ja) 2019-08-19 2025-07-10 デオキシシチジンの多形形態、それを含む組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116467A Pending JP2025160233A (ja) 2019-08-19 2025-07-10 デオキシシチジンの多形形態、それを含む組成物および使用

Country Status (8)

Country Link
US (1) US11649259B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017502A4 (cg-RX-API-DMAC7.html)
JP (2) JP7769603B2 (cg-RX-API-DMAC7.html)
CN (1) CN114929240B (cg-RX-API-DMAC7.html)
AU (1) AU2020334060B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022002513A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150755A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021034962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof
WO2026082601A2 (en) * 2024-10-15 2026-04-23 UCB Biopharma SRL Method of purification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521993A (ja) 2015-06-17 2018-08-09 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ミトコンドリアdna枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898936A (en) * 1984-09-24 1990-02-06 Pcr, Inc. 2-deoxyuridines and riboside precursors
JPS61135597A (ja) * 1984-12-06 1986-06-23 Takeda Chem Ind Ltd シチジンおよびデオキシシチジンの製造法
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
JP2002255991A (ja) * 2000-12-27 2002-09-11 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の製造法
JP2002293791A (ja) * 2001-03-30 2002-10-09 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の精製法
CN100424091C (zh) * 2002-06-05 2008-10-08 三井化学株式会社 保护化2’-脱氧胞苷类的精制法
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US9669048B2 (en) * 2012-10-25 2017-06-06 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
GB2580963C (en) * 2019-02-01 2025-09-03 Hemispherian As Cancer therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521993A (ja) 2015-06-17 2018-08-09 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ミトコンドリアdna枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Molechlar Structure,1998年,Vol. 448,pp. 177-183
Tetrahedron,1992年,Vol. 48, No. 23,pp. 4893-4904
医薬品の残留溶媒ガイドラインについて,独立行政法人 医薬品医療機器総合機構[オンライン],[検索日2024.06.24],1998年,インターネット<URL:https://www.pmda.go.jp/files/000156502.pdf>

Also Published As

Publication number Publication date
AU2020334060A1 (en) 2022-03-24
US20210054014A1 (en) 2021-02-25
EP4017502A4 (en) 2023-11-01
CN114929240A (zh) 2022-08-19
JP2025160233A (ja) 2025-10-22
EP4017502A1 (en) 2022-06-29
CA3150755A1 (en) 2021-02-25
CN114929240B (zh) 2024-10-29
AU2020334060B2 (en) 2024-11-14
JP2022544831A (ja) 2022-10-21
US11649259B2 (en) 2023-05-16
BR112022002513A2 (pt) 2022-05-03
WO2021034962A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
CN110636884B (zh) 新结晶形式
JP2025160233A (ja) デオキシシチジンの多形形態、それを含む組成物および使用
TWI920053B (zh) 2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧環丁烷-3-基)哌-1-基]戊-2-烯腈之晶形
US20220017548A1 (en) Compounds and Methods for the Treatment of COVID-19
CN116726035A (zh) 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法
BR112013001553A2 (pt) Métodos e compostos para tratar infecções por vírus paramyxoviridae
US20230414519A1 (en) Rapidly infusing compositions with methotrexate and treatment methods
US20230151048A1 (en) Crystal form, preparation method, and application of 4′-substituted nucleoside
TWI326687B (en) Amide prodrug of gemcitabine, compositions and use thereof
EP4547334A1 (en) Solid forms of a nucleoside analogue and uses thereof
BR112020002984A2 (pt) terapia combinada
KR20060127906A (ko) 4&#39;-치환된 카보버와 아바카비어 유도체 및 hiv와 hcv항바이러스 활성을 갖는 관련 화합물
JP2021521210A (ja) 不均衡なヌクレオチドプールによって引き起こされた疾患を治療するためのデオキシヌクレオシドのプロドラッグ
US20210161909A1 (en) Combination therapy
WO2009064174A1 (en) Polymorphic form of tenofovir disoproxil fumarate, method for its preparation and use
CN102770416B (zh) 美他沙酮共晶体
BR112019014825A2 (pt) Composição farmacêutica compreendendo um derivado de oxazina e seu uso no tratamento ou prevenção da doença de alzheimer
US20220340549A1 (en) Crystalline form of cxcr2 antagonist and application thereof
WO2023105483A1 (en) Crystalline forms of a 5-aminopyrazole compound useful for treating hbv
CN112010905B (zh) 甲磺酸帕拉德福韦晶型及其应用
ES2892402T3 (es) Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
RU2787616C2 (ru) Гемисульфатная соль нуклеотида для лечения вируса гепатита с
HK40069164A (en) Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
HK40070765A (en) 2-oxo-3-pyrrolidinylpropionitrile compounds and their pharmaceutical compositions and uses
CN116829153A (zh) 治疗流感化合物的晶型及应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230817

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241001

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251031

R150 Certificate of patent or registration of utility model

Ref document number: 7769603

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150